{
    "title": "107_hr1530",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Drug Competition Act of \n2001''.\n\nSEC. 2. FINDINGS.\n\n    Congress finds that--\n            (1) prescription drug costs are increasing at an alarming \n        rate and are a major concern of senior citizens and American \n        families;\n            (2) there is a potential for drug companies owning patents \n        on brand-name drugs to enter to private financial deals with \n        generic drug companies in a manner that could tend to restrain \n        trade and greatly reduce competition and increase prescription \n        drug costs for American citizens; and\n            (3) enhancing competition between generic drug \n        manufacturers and brand name manufacturers can significantly \n        reduce prescription drug costs to American families.\n\nSEC. 3. PURPOSE.\n\n    The purposes of this Act are--\n            (1) to provide timely notice to the Food and Drug \n        Administration and the Federal Trade Commission regarding \n        agreements between companies owning patents on branded drugs \n        and companies who could manufacture generic or bioequivalent \n        versions of such branded drugs; and\n            (2) by providing timely notice, to--\n                    (A) ensure the prompt availability of safe and \n                effective generic drugs;\n                    (B) enhance the effectiveness and efficiency of the \n                enforcement of the antitrust laws of the United States; \n                and\n                    (C) deter pharmaceutical companies from engaging in \n                anticompetitive actions or actions that tend to \n                unfairly restrain trade.\n\nSEC. 4. DEFINITIONS.\n\n    In this Act:\n            (1) Agreement.--The term ``agreement'' means an agreement \n        under section 1 of the Sherman Act (15 U.S.C. 1) or section 5 \n        of the Federal Trade Commission Act (15 U.S.C. 45).\n            (2) Antitrust laws.--The term ``antitrust laws'' has the \n        same meaning as in section 1 of the Clayton Act (15 U.S.C. 12), \n        except that such term includes section 5 of the Federal Trade \n        Commission Act (15 U.S.C. 45) to the extent that such section \n        applies to unfair methods of competition.\n            (3) ANDA.--The term ``ANDA'' means an Abbreviated New Drug \n        Application, as defined under section 505(j) of the Federal \n        Food, Drug and Cosmetic Act.\n            (4) Brand name drug company.--The term ``brand name drug \n        company'' means a person engaged in the manufacture or \n        marketing of a drug approved under section 505(b) of the \n        Federal Food, Drug and Cosmetic Act.\n            (5) Commission.--The term ``Commission'' means the Federal \n        Trade Commission.\n            (6) FDA.--The term ``FDA'' means the United States Food and \n        Drug Administration.\n            (7) Generic drug.--The term ``generic drug'' means a \n        product that is the subject of an ANDA.\n            (8) Generic drug applicant.--The term ``generic drug \n        applicant'' means a person who has filed or received approval \n        for an ANDA under section 505(j) of the Federal Food, Drug and \n        Cosmetic Act.\n            (9) Secretary.--The term ``Secretary'' means the Secretary \n        of Health and Human Services.\n\nSEC. 5. NOTIFICATION OF AGREEMENTS AFFECTING THE SALE OR MARKETING OF \n              GENERIC DRUGS.\n\n    A brand name drug company and a generic drug applicant that enter \ninto an agreement regarding the sale or manufacture of a generic drug \nthat the Secretary has determined is the therapeutic equivalent of a \nbrand name drug that is manufactured or marketed by that brand name \ndrug company, or for which the generic drug applicant seeks such a \ndetermination of therapeutic equivalence, and which agreement could \nhave the effect of limiting the research, development, manufacture, \nmarketing, or selling of a generic drug that has been or could be \napproved for sale by the FDA pursuant to an ANDA, shall file with the \nCommission and the Secretary the text of the agreement, an explanation \nof the purpose and scope of the agreement, and an explanation of \nwhether the agreement could delay, restrain, limit, or in any way \ninterfere with the production, manufacture, or sale of the generic \nversion of the drug in question.\n\nSEC. 6. FILING DEADLINES.\n\n    Any notice, agreement, or other material required to be filed under \nsection 5 shall be filed with the Commission and the Secretary not \nlater than 10 business days after the date the agreement is executed.\n\nSEC. 7. ENFORCEMENT.\n\n    (a) Civil Fine.--Any person, or any officer, director, or partner \nthereof, who fails to comply with any provision of this Act shall be \nliable for a civil penalty of not more than $20,000 for each day during \nwhich such person is in violation of this Act. Such penalty may be \nrecovered in a civil action brought by the United States, or brought by \nthe Commission in accordance with the procedures established in section \n16(a)(1) of the Federal Trade Commission Act (15 U.S.C. 56(a)).\n    (b) Compliance and Equitable Relief.--If any person, or any \nofficer, director, partner, agent, or employee thereof, fails to comply \nwith the notification requirement under section 5 of this Act, the \nUnited States district court may order compliance, and may grant such \nother equitable relief as the court in its discretion determines \nnecessary or appropriate, upon application of the Commission or the \nAssistant Attorney General.\n\nSEC. 8. RULEMAKING.\n\n    The Commission, in consultation with the Secretary, and with the \nconcurrence of the Assistant Attorney General and by rule in accordance \nwith section 553 of title 5, United States Code, consistent with the \npurposes of this Act--\n            (1) may require that the notice described in section 5 of \n        this Act be in such form and contain such documentary material \n        and information relevant to the agreement as is necessary and \n        appropriate to enable the Commission and the Assistant Attorney \n        General to determine whether such agreement may violate the \n        antitrust laws;\n            (2) may define the terms used in this Act;\n            (3) may exempt classes of persons or agreements from the \n        requirements of this Act; and\n            (4) may prescribe such other rules as may be necessary and \n        appropriate to carry out the purposes of this Act.\n\nSEC. 9. EFFECTIVE DATES.\n\n    This Act shall take effect 90 days after the date of enactment of \nthis Act."
}